Adenosine Phosphate

Adenosine Phosphate

SCHEMBL3176912

NO.Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RY1 P47900 5/20 0.98
▸ P2RY2 P41231 3/20 0.98
▸ SRC P12931 2/20 0.98
▸ SMN1; SMN2 Q16637 2/20 0.98
▸ TRPM2 O94759 2/20 0.98
▸ TAS1R3 Q7RTX0 2/20 0.98
▸ TAS1R1 Q7RTX1 2/20 0.98
▸ DNPH1 O43598 1/20 0.98
▸ PRKAB2 O43741 1/20 0.98
▸ LDHA P00338 1/20 0.98
▸ ADRB2 P07550 1/20 0.98
▸ FBP1 P09467 1/20 0.98
▸ ADORA1 P30542 1/20 0.98
▸ PRKAG1 P54619 1/20 0.98
▸ PRKAA2 P54646 1/20 0.98
▸ PDE4D Q08499 1/20 0.98
▸ KCNH2 Q12809 1/20 0.98
▸ PRKAA1 Q13131 1/20 0.98
▸ PDE3A Q14432 1/20 0.98
▸ P2RY11 Q96G91 1/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenosine Phosphate SCHEMBL8572634 0.99 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL144997 0.99 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL13374692 0.99 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL2683103 0.99 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL15646670 0.99 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Vidarabine Phosphate SCHEMBL144996 0.99 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL20277555 0.99 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL18785114 0.99 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL5588 0.99 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL14478782 0.99 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407544-B2 Titanium dioxide pigment and manufacturing method TRONOX LLC (US) 2019-09-10 — — US disclosed
EP-2066300-B2 SELF-PRESERVED AQUEOUS PHARMACEUTICAL COMPOSITIONS NOVARTIS AG (CH) 2019-01-23 — — EP disclosed
US-20190010287-A1 TITANIUM DIOXIDE PIGMENT AND MANUFACTURING METHOD WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT 2019-01-10 — — US disclosed
US-10125219-B2 Titanium dioxide pigment and manufacturing method TRONOX LLC (US) 2018-11-13 — — US disclosed
US-9862797-B2 Sterically hindered aliphatic polyamine cross-linking agents, compositions containing them and uses thereof CONNORA TECHNOLOGIES, INC. (US) 2018-01-09 — — US disclosed
EP-2117300-B1 AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS ANGUS CHEMICAL (US) 2017-04-19 — — EP disclosed
US-20160264717-A1 STERICALLY HINDERED ALIPHATIC POLYAMINE CROSS-LINKING AGENTS, COMPOSITIONS CONTAINING THEM AND USES THEREOF ADITYA BIRLA CHEMICALS (USA), INC. 2016-09-15 — — US disclosed
US-20160122472-A1 TITANIUM DIOXIDE PIGMENT AND MANUFACTURING METHOD WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT 2016-05-05 — — US disclosed
EP-3015511-A1 TITANIUM DIOXIDE PIGMENT AND MANUFACTURING METHOD Tronox LLC (US) 2016-05-04 — — EP disclosed
EP-2066300-B1 SELF-PRESERVED AQUEOUS PHARMACEUTICAL COMPOSITIONS ALCON RES LTD (US) 2015-06-17 — — EP disclosed
US-20100093736-A1 AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS ANGUS CHEMICAL COMPANY (US) 2010-04-15 — — US disclosed
US-20100021562-A1 SELF PRESERVED AQUEOUS PHARMACEUTICAL COMPOSITIONS NOVARTIS AG (CH) 2010-01-28 — — US disclosed
US-20100021561-A1 SELF-PRESERVED AQUEOUS PHARMACEUTICAL COMPOSITIONS ALCON RESEARCH, LTD. 2010-01-28 — — US disclosed
CN-101631457-A Amino alcohol and biocide compositions for aqueous based systems ANGUS CHEMICAL 2010-01-20 — — CN disclosed
EP-2117300-A2 AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS ANGUS CHEMICAL COMPANY (US) 2009-11-18 — — EP disclosed
CN-101522171-A Self-preserved aqueous pharmaceutical compositions ALCON MFG LTD (US) 2009-09-02 — — CN disclosed
EP-2066300-A2 SELF-PRESERVED AQUEOUS PHARMACEUTICAL COMPOSITIONS Alcon Research, Ltd. (US) 2009-06-10 — — EP disclosed
WO-2008088632-A2 AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS ANGUS CHEMICAL COMPANY (US) 2008-07-24 — — WO disclosed
WO-2008042619-A2 SELF-PRESERVED AQUEOUS PHARMACEUTICAL COMPOSITIONS ALCON RESEARCH, LTD. (US) 2008-04-10 — — WO disclosed
WO-2008036855-A2 SELF-PRESERVED AQUEOUS PHARMACEUTICAL COMPOSITIONS ALCON RESEARCH, LTD. (US) 2008-03-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093736-A1 AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS ADH1C, ADH1A, ADH5 P2RY1 3650/4885P2RY2 4256/4885SRC 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback